Select region
Menu
  • Products and Solutionsmore
    • Intensive Care
    • Cardiovascular Procedures
    • Operating Room
    • Sterile Reprocessing
    • Digital Health
    • Pharmaceutical Production
    • Research Laboratories

    • View all products →
  • Servicesmore
    • Technical Services
    • Digital Services
    • Financial Services
    • Planning and Design
    • Project Implementation
    • Education and Training
    • Hospital Transformational Partnerships

    • View all Services →
  • Insightsmore
    • Academy
    • Articles
    • Hendelser
    • Getinge Experience Center
    • Idea and invention submission

    • Insights main page →
  • Companymore
    • Corporate Governance
    • Sustainability
    • Business Ethics
    • News
    • Careers
    • Investors
    • Grants and Charitable Donations
    • History

    • Company main page →
    • News
    • Legal Information
    • Instructions For Use/Patient Information
    • Product Catalog
    • COVID-19 Resource Center
    • Investors
    • Careers
  • Kontakt
  • Norge (Norsk)
    • Global
      • International (English)
    • EMEA
      • Sverige (Svenska)
      • Deutschland (Deutsch)
      • France (Français)
      • United Kingdom / Ireland (English)
      • Italia (Italiano)
      • Türkiye (Türkçe)
      • Polska (polski)
      • Россия (русский)
      • Spain (Español)
      • Denmark (Dansk)
      • Norge (Norsk)
      • Suomi (Suomalainen)
      • Benelux (Nederlands)
    • Americas
      • United States (English)
      • Brazil (Português)
      • Canada (English)
      • Canada (Français)
      • Latin America (Español)
    • Asia
      • 日本 (日本語)
      • 中国 (中文)
      • 한국어(대한민국)
      • South East Asia (English)
      • India (English)
    • Oceania
      • Australia / New Zealand (English)
  • Products and Solutions
    • Intensive Care
    • Cardiovascular Procedures
    • Operating Room
    • Sterile Reprocessing
    • Digital Health
    • Pharmaceutical Production
    • Research Laboratories

    • View all products →
  • Services
    • Technical Services
    • Digital Services
    • Financial Services
    • Planning and Design
    • Project Implementation
    • Education and Training
    • Hospital Transformational Partnerships

    • View all Services →
  • Insights
    • Academy
    • Articles
    • Hendelser
    • Getinge Experience Center
    • Idea and invention submission

    • Insights main page →
  • Company
    • Corporate Governance
    • Sustainability
    • Business Ethics
    • News
    • Careers
    • Investors
    • Grants and Charitable Donations
    • History

    • Company main page →
  • Kontakt
  • Start
  • Insights
  • Articles
  • Operating Room
  • Low-flow anesthesia
  • Why low-flow anesthesia?
  • Low-flow anesthesia offers pulmonary, economic and environmental benefits
  • Should we change to low- or minimal-flow anesthesia?
  • Theory and practice of minimal fresh gas flow anesthesia
  • What are potential risks of low-flow anesthesia?

Low-flow anesthesia

Topic
Operating Room
Patient under anesthesia
Topic
Operating Room

Why low-flow anesthesia?

Already in 1924 RM Waters published an article in Anesthesia and Analgesia where he presents improved economy, convenience and welfare of the patients as the benefits of using a re-breathing system during anesthesia [1]. This is still true today but we can also add welfare of the planet as another major benefit.

Low-flow anesthesia offers pulmonary, economic and environmental benefits

In low-flow anesthesia, a rebreathing system uses a fresh gas flow (FGF) that is less than the alveolar ventilation of the patient. This technique uses less anesthetic agents than conventional systems, emits less gas into the atmosphere, and improves the flow dynamics of the inhaled air. Low flow is generally characterized by a fresh gas flow of less than 1.0 L/min. In minimal flow, the FGF is decreased to 0.5 L/min.

Should we change to low- or minimal-flow anesthesia?

Reducing the fresh gas flow has several benefits:

web-anesthesia-low-flow-icon-economy-120x120.jpg

Economy

Agent expenditure accounts for a large part of the total cost of ownership of anesthesia machines. Reducing the anesthetic agent consumption in your ORs will have a positive impact on your overall hospital expenditure.

web-anesthesia-low-flow-environmental-120x120.jpg

Environmental impact

With low-flow anesthesia, a lower amount of anesthetic agent is released into the environment, reducing the impact of fluorocarbons and nitrous oxide on the ozone layer, thus reducing the overall greenhouse gas emissions.

web-anesthesia-low-flow-patient-safety-120x120.jpg

Patient comfort and safety

Low FGF improves the flow dynamics of inhaled gases, increases mucociliary clearance, maintains body temperature and reduces water loss. 

web-anesthesia-low-flow-staff-safety-120x120.jpg

OR staff safety

With less unused surplus gas discharged into the atmosphere, the concentration of anesthesia gas in the OR is greatly reduced. This minimizes occupational risk for OR staff.

Theory and practice of minimal fresh gas flow anesthesia

The review by Brattwall et al. in the Canadian Journal of Anesthesia, outlines the benefits of minimal fresh gas flow anesthesia.  It provides practical guidance on safe implementation of low- and minimal-flow anesthesia in routine clinical practice. [2]

What are potential risks of low-flow anesthesia?

Hypoxic mixtures

The formation of hypoxic mixtures are one of the greatest risk of using low-flow anesthesia. Reducing fresh gas flow in a rebreathing circle system results in a difference between the delivered O2 concentration(FD) at the common gas outlet and the inspired O2 (FIO2). Consequently, FIO2 becomes lower than the fraction of delivered oxygen (FDO2). This may not always be sufficiently recognized, and if settings are not adjusted, hypoxic mixtures can develop. An active inspired hypoxic guard has been shown to prevent the formation of hypoxic mixtures.

Learn how to avoid hypoxic mixtures

Inadequate depth of anesthesia

During low-flow anesthesia there is a potential risk for inadequate anesthetic gas concentration. An automatic gas control (AGC) system removes the need for continuous manual adjustments of FGF, FIO2 and EtAA. Targeting FIO2 directly will help avoid hypoxia. Targeting EtAA at the desired speed will reduce the risk of under- or overdosing.

Learn more about our Automatic Gas Control (AGC)

Related Articles

View all

Enkel onboarding av nye medarbeidere ved sterilsentralen

Gi veiledning til uerfarne medarbeidere og tilpass prosessene til ulike brukerkompetansenivåer, samtidig som dere opprettholder et høyt og konsekvent kvalitetsnivå i den sterile produksjonen

Digital Health
Operating Room
Sterile Reprocessing

Integrer sykehusets IT-løsninger

T-DOC binder sammen sykehusets IT-infrastruktur for å sikre smidigere prosesser, økt kvalitet og sømløs kommunikasjon.

Digital Health
Operating Room
Sterile Reprocessing

Operasjoner kan ikke vente – sørg for korrekt levering av prosedyrevogner

Med T-DOC, vår smarte administrasjon av sterile forsyninger, kan sterilavdelingen sikre at kirurgiske prosedyrevogner leveres til operasjonsstuen i tide.

Digital Health
Operating Room
Sterile Reprocessing

All references

  1. 1. Waters R.M 1924 Clinical scope and utility of carbon dioxid filtration in inhalation anesthesia. Anesthesia and Analgesia Feb p 20-22, 26

  2. 2. Brattwall M, et al. Brief review: Theory and practice of minimal fresh gas flow anesthesia. Can J Anesth/J Can Anesth (2012) 59:785–797

Du forlater nå Getinge.com. Du kan få tilgang til innhold som ikke administreres av Getinge-teamet, i så fall kan ikke Getinge holdes ansvarlig for innholdet.

Jeg forstår!

Our offer

  • Products and Solutions
  • Services

Support and tools

  • Insights
  • Events
  • Past Webinars
  • Instructions For Use/Patient Information
  • Security

Company

  • Investors
  • Careers
  • Corporate Governance
  • Legal Information
  • The Norwegian transparency act 2025 statement
  • Website Privacy Policy
  • Website use disclaimer
  • Cookie Notice
  • Data Subject Request Form
Ta kontakt med oss
Norge (Norsk)
  • Global
    • International (English)
  • EMEA
    • Sverige (Svenska)
    • Deutschland (Deutsch)
    • France (Français)
    • United Kingdom / Ireland (English)
    • Italia (Italiano)
    • Türkiye (Türkçe)
    • Polska (polski)
    • Россия (русский)
    • Spain (Español)
    • Denmark (Dansk)
    • Norge (Norsk)
    • Suomi (Suomalainen)
    • Benelux (Nederlands)
  • Americas
    • United States (English)
    • Brazil (Português)
    • Canada (English)
    • Canada (Français)
    • Latin America (Español)
  • Asia
    • 日本 (日本語)
    • 中国 (中文)
    • 한국어(대한민국)
    • South East Asia (English)
    • India (English)
  • Oceania
    • Australia / New Zealand (English)
Norge (Norsk)

© 2025 Getinge │ Getinge og

Getinge_Logo_hz_RGB_neg.png

er varemerker eller registrerte varemerker som tilhører Getinge AB, dets datterselskaper eller tilknyttede selskaper │ Alle rettigheter forbeholdes.

mars 2025

Denne informasjonen er utelukkende ment for helsepersonell eller andre fagpersoner og er bare til orientering. Den er ikke uttømmende og erstatter derfor ikke bruksanvisningen, servicehåndboken eller medisinsk rådgivning. Getinge er ikke ansvarlig for det andre parter gjør eller ikke gjør på bakgrunn av dette materialet, og brukeren bærer risikoen for sin bruk av materialet.

Det er ikke sikkert behandlinger, løsninger eller produkter som nevnes i materialet, er tilgjengelige eller tillatt i det landet hvor du bor. Informasjonen kan verken helt eller delvis kopieres eller brukes uten skriftlig tillatelse fra Getinge.

Denne informasjonen er ment for et internasjonalt publikum utenfor USA.

De synspunkter, meninger og påstander som kommer til uttrykk, tilhører kun de intervjuede. De gjenspeiler eller representerer ikke nødvendigvis Getinges synspunkter.